- Home
- KXIN vs MTVA Comparison
KXIN vs MTVA Comparison
Compare KXIN & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- MTVA
- Stock Information
- Founded
- KXIN 2015
- MTVA 2014
- Country
- KXIN China
- MTVA United States
- Employees
- KXIN N/A
- MTVA N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- MTVA
- Sector
- KXIN Consumer Discretionary
- MTVA
- Exchange
- KXIN Nasdaq
- MTVA NYSE
- Market Cap
- KXIN 13.0M
- MTVA 14.3M
- IPO Year
- KXIN N/A
- MTVA N/A
- Fundamental
- Price
- KXIN $0.90
- MTVA $0.65
- Analyst Decision
- KXIN
- MTVA Strong Buy
- Analyst Count
- KXIN 0
- MTVA 2
- Target Price
- KXIN N/A
- MTVA $7.50
- AVG Volume (30 Days)
- KXIN 80.5K
- MTVA 125.1K
- Earning Date
- KXIN 01-01-0001
- MTVA 08-13-2025
- Dividend Yield
- KXIN N/A
- MTVA N/A
- EPS Growth
- KXIN N/A
- MTVA N/A
- EPS
- KXIN N/A
- MTVA N/A
- Revenue
- KXIN N/A
- MTVA N/A
- Revenue This Year
- KXIN N/A
- MTVA N/A
- Revenue Next Year
- KXIN N/A
- MTVA N/A
- P/E Ratio
- KXIN N/A
- MTVA N/A
- Revenue Growth
- KXIN N/A
- MTVA N/A
- 52 Week Low
- KXIN $0.64
- MTVA $0.63
- 52 Week High
- KXIN $29.54
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- KXIN 53.15
- MTVA N/A
- Support Level
- KXIN $0.90
- MTVA N/A
- Resistance Level
- KXIN $1.10
- MTVA N/A
- Average True Range (ATR)
- KXIN 0.06
- MTVA 0.00
- MACD
- KXIN 0.01
- MTVA 0.00
- Stochastic Oscillator
- KXIN 48.98
- MTVA 0.00
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.